Skip to main content

Table 3 Interaction of ABT-737 (0.5 µM) with doxorubicin (1.0 µM a), gemcitbine (0.5 µM b) or cisplatin (5.0 µM c) in five thyroid carcinoma cell lines

From: The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells

(a) Cell line ABT-737 Doxorubicin ABT-737 + doxorubicin CI
FTC236 (FTC)) 96.2 ± 6.5 92.4 ± 4.2 68.4 ± 5.9 1.30 syn.
ML1 (FTC) 86.5 ± 7.3 75.9 ± 5.4 37.6 ± 1.5 1.75 syn.
BHT101 (PTC) 84.4 ± 5.5 90.1 ± 6.1 78.6 ± 6.7 0.97 add.
SW1736 (ATC) 95.6 ± 7.0 74.3 ± 4.8 34.7 ± 3.0 2.05 syn.
HTh7 (ATC) 98.6 ± 4.6 65.0 ± 5.5 62.2 ± 3.1 1.03 add.
(b) Cell line ABT-737 Gemcitabine ABT-737 + gemcitabine CI
FTC236 (FTC) 99.1 ± 4.8 79.4 ± 4.8 61.3 ± 5.0 1.28 syn.
ML1 (FTC) 86.0 ± 5.3 83.2 ± 5.4 54.8 ± 3.8 1.31 syn.
BHT101 (PTC) 84.9 ± 6.9 87.6 ± 6.7 76.2 ± 5.2 0.98 add.
SW1736 (ATC) 96.8 ± 6.1 78.5 ± 3.8 56.1 ± 2.5 1.35 syn.
HTh7 (ATC) 97.3 ± 7.5 71.8 ± 4.2 42.9 ± 3.9 1.63 syn.
(c) Cell line ABT-737 Cisplatin ABT-737 + cisplatin CI
FTC236 (FTC) 95.9 ± 7.9 102.6 ± 9.3 99.7 ± 7.4 0.99 add.
ML1 (FTC) 84.8 ± 5.8 97.3 ± 7.4 83.5 ± 6.9 0.99 add.
BHT101 (PTC) 83.4 ± 6.3 98.1 ± 8.7 81.7 ± 5.7 1.00 add.
SW1736 (ATC) 95.0 ± 5.6 103.8 ± 7.2 101.9 ± 6.9 0.97 add.
HTh7 (ATC) 99.3 ± 7.8 98.5 ± 5.9 100.2 ± 7.0 0.98 add.
  1. MTT assays were performed to determine the viability of cells after incubation with one compound alone or in combination. Cl values were calculated according to the method of Drewinko et al. [34; see “Methods” section], where Cl > 1.05 indicates synergism (syn.), 0.95 ≤ Cl ≤ 1.05 indicates additivity (add.) and Cl < 0.95 indicates antagonism